Affinage

CXCL8

Interleukin-8 · UniProt P10145

Length
99 aa
Mass
11.1 kDa
Annotated
2026-06-09
100 papers in source corpus 29 papers cited in narrative 28 extracted findings
Cross-family judge vs UniProt: tie faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CXCL8 (IL-8/MDNCF) is a secreted CXC chemokine that functions as a potent neutrophil chemoattractant and broader effector of inflammation, angiogenesis, and tissue remodeling, originally cloned as an IL-1/TNF/LPS-inducible product of human monocytes that is synthesized as a 99-amino-acid precursor and processed to a 72-amino-acid mature form (PMID:3260265). It signals through two distinct high-affinity neutrophil receptor polypeptides (~67 kDa and ~59 kDa) (PMID:2647892), later resolved as CXCR1 and CXCR2, with its NH₂-terminal region (AVLPRSAKEL) sufficient to drive chemotaxis (PMID:2675839). The CXCL8 monomer is more potent than the dimer for calcium mobilization, chemotaxis, and exocytosis, and engages the two receptors differentially—the monomer preferentially driving CXCR1 phosphorylation, β-arrestin recruitment, and internalization while both forms act equivalently on CXCR2 (PMID:19667085). Receptor engagement activates PI3K/Akt–Cbl, ERK, and RhoA/Cdc42 cascades that drive chemotaxis, cytoskeletal remodeling, and invasion in neutrophils, endothelial, and tumor cells (PMID:16798838, PMID:21749879, PMID:31986121). CXCL8 activity is fine-tuned post-translationally: NH₂-terminal proteolytic truncation selectively potentiates actin polymerization and in vivo recruitment (PMID:32272490), while PAD-mediated citrullination at Arg5 reduces glycosaminoglycan affinity, dampens CXCR2 signaling, and abolishes neutrophil extravasation in vivo (PMID:18710930). Its transcription is inducibly controlled through an NF-κB site downstream of thrombin–PAR1/PAR4–PKCα–c-Src–IKK signaling (PMID:16920985), a DCLK1–RhoA–YAP/p65 axis (PMID:36369000), and cytonuclear ZO-1 (PMID:28057697, PMID:22064657), through NFAT/AP1 downstream of PGF₂α–FP receptor–calcineurin (PMID:19819266), and is negatively regulated by KLF4 binding the promoter (PMID:34038586). Beyond acute neutrophil recruitment, CXCL8/CXCR2 signaling drives pathological programs including bone marrow fibrosis in myelofibrosis (PMID:36800567), glioblastoma stem-cell self-renewal and macrophage M2 polarization (PMID:37439870), chondrocyte hypertrophy and matrix calcification via p38/TG2 (PMID:14530367), and is co-opted by enteroviruses to enhance viral replication via MAPK-driven hnRNP-K relocalization (PMID:39962077).

Mechanistic history

Synthesis pass · year-by-year structured walk · 28 steps
  1. 1988 High

    Establishing CXCL8's molecular identity and inducibility answered whether a discrete cytokine-inducible neutrophil chemoattractant existed, defining the precursor-to-mature processing and its regulation by IL-1/TNF.

    Evidence cDNA cloning and N-terminal sequencing of MDNCF from LPS-stimulated monocytes with IL-1/TNF mRNA induction assays

    PMID:3260265

    Open questions at the time
    • Did not identify the receptor
    • Processing protease not defined
    • Transcriptional control elements not mapped
  2. 1989 High

    Identification of distinct high-affinity neutrophil receptor polypeptides showed CXCL8 acts through dedicated receptors separate from other chemoattractant systems, establishing a specific receptor-mediated signaling axis.

    Evidence Radioligand binding, Scatchard analysis, and chemical cross-linking of receptor-ligand complexes on human neutrophils

    PMID:2647892

    Open questions at the time
    • Receptor genes/sequences not cloned here
    • Downstream signaling not defined
    • Relationship of two polypeptides to CXCR1/CXCR2 not yet established
  3. 1989 Medium

    Mapping chemotactic activity to the NH₂-terminal decapeptide defined the structural determinant for receptor activation versus granule release, separating chemotaxis from degranulation.

    Evidence Synthetic N-terminal peptide chemotaxis, phosphorylation, and enzyme-release assays in PMNs

    PMID:2675839

    Open questions at the time
    • Single-lab in vitro peptide study
    • Receptor binding affinity of peptide not quantified
    • Structural basis incomplete
  4. 1990 High

    Determining gene location, exon-intron structure, and N-terminal truncation answered how CXCL8 relates to the chemokine cluster and revealed proteolytic generation of distinct mature forms.

    Evidence Somatic cell hybrid mapping, in situ hybridization, genomic PCR and RFLP

    PMID:1967588 PMID:2200751

    Open questions at the time
    • Functional consequence of truncation not yet assayed
    • Responsible proteases unidentified
  5. 2003 High

    Linking CXCL8/CXCR1-2 to chondrocyte hypertrophy via p38 and TG2 extended its role beyond chemotaxis into pathological tissue mineralization.

    Evidence Primary chondrocytes, p38 inhibition, TG2-null mouse cells, calcification and marker assays

    PMID:14530367

    Open questions at the time
    • Mechanism connecting p38 to TG2 not detailed
    • Relevance to human osteoarthritis in vivo not established
  6. 2005 Medium

    Mapping repertaxin to a transmembrane allosteric site on CXCR1 defined a druggable noncompetitive mode of CXCL8-signaling inhibition.

    Evidence Molecular modeling, alanine-scanning mutagenesis, photoaffinity labeling

    PMID:15974585

    Open questions at the time
    • Single-lab structural model
    • CXCR2 site not directly resolved
  7. 2006 High

    Defining the thrombin–PAR1/4–PKCα–c-Src–IKK–NF-κB cascade established how coagulation signaling drives CXCL8 transcription at the promoter κB site.

    Evidence Dominant-negative c-Src, PAR agonists, κB-mutant luciferase, co-IP of PKCα/c-Src/IKK, kinase assays in lung epithelial cells

    PMID:16920985

    Open questions at the time
    • Generality beyond lung epithelium untested
    • Cross-talk with other promoter elements unresolved
  8. 2006 Medium

    Implicating PI3K/Akt and Cbl in CXCL8-driven chemotaxis and proteasome-dependent receptor internalization clarified the intracellular machinery linking receptor engagement to migration.

    Evidence Mutant Cbl/Akt overexpression, PI3K inhibition, p85-Cbl co-IP, proteasome-inhibitor internalization assays in CXCR1/2 cells

    PMID:16798838

    Open questions at the time
    • Single-lab study
    • Cbl substrate(s) in this pathway not identified
  9. 2008 High

    Discovery of natural Arg5 citrullination defined a post-translational switch that lowers GAG affinity and CXCR2 signaling and uncouples in vitro chemotaxis from in vivo extravasation.

    Evidence Natural CXCL8 isolation, PAD citrullination, calcium/ERK assays, in vivo peritoneal recruitment and corneal angiogenesis

    PMID:18710930

    Open questions at the time
    • Physiological PAD source in vivo not pinpointed
    • Receptor-level structural basis not resolved here
  10. 2008 Medium

    Showing Thy-1–Mac-1 engagement triggers neutrophil CXCL8 and MMP-9 secretion identified an adhesion-coupled feed-forward loop enhancing transmigration.

    Evidence Neutrophil adhesion to recombinant Thy-1, anti-Thy-1/CD18 blockade, ELISA and migration assays

    PMID:18389476

    Open questions at the time
    • Single-lab study
    • Intracellular signaling from Mac-1 to CXCL8 secretion not mapped
  11. 2009 High

    Engineered monomer/dimer-locked variants resolved that the monomer is the more potent signaling species and that monomer/dimer balance differentially governs CXCR1 versus CXCR2 regulation.

    Evidence L25NMe monomer and R26C dimer variants across Ca2+, PI hydrolysis, chemotaxis, β-arrestin, internalization assays in neutrophils and RBL cells

    PMID:19667085

    Open questions at the time
    • In vivo relevance of oligomeric state not fully resolved
    • Structural basis of receptor-specific bias not detailed
  12. 2009 Medium

    Defining the PGF₂α–FP–PKC–calcineurin–NFAT/AP1 pathway and RCAN1-4 feedback established an NF-κB-independent transcriptional route to CXCL8 in tumor cells.

    Evidence Promoter mutants, PKC inhibitors, calcium chelation, adenoviral RCAN1-4, nude mouse xenograft

    PMID:19819266

    Open questions at the time
    • Single-lab study
    • Relative contribution versus NF-κB route unquantified
  13. 2011 Medium

    ZO-1 was identified as a positive transcriptional regulator of CXCL8 in breast cancer independent of β-catenin, linking a junctional protein to chemokine output.

    Evidence Three independent ZO-1 siRNAs, cDNA overexpression, CXCL8 luciferase promoter assay

    PMID:22064657

    Open questions at the time
    • Promoter element for ZO-1 action not yet localized here
    • Mechanism of cytonuclear ZO-1 not defined
  14. 2011 Medium

    CXCR1/CXCR2 requirement for endothelial proliferation, migration, invasion, and tube formation established CXCL8's direct pro-angiogenic action via ERK and cytoskeletal remodeling.

    Evidence shRNA knockdown of CXCR1/CXCR2 in HMEC-1 cells with ERK and phenotypic assays

    PMID:21749879

    Open questions at the time
    • Single-lab study
    • Relative roles of CXCR1 vs CXCR2 not fully dissected
  15. 2017 Medium

    Defining the cytonuclear ZO-1–NF-κB–CXCL8 axis driving angiogenesis explained how ZO-1 activates the promoter through p65 phosphorylation at a defined κB region.

    Evidence ZO-1 siRNA/cDNA, κB-mutant luciferase, p65 siRNA, ex vivo and in vivo angiogenesis

    PMID:28057697

    Open questions at the time
    • Single-lab study
    • How cytoplasmic ZO-1 reaches/regulates NF-κB mechanistically incomplete
  16. 2018 Medium

    Comparing citrullinated and truncated isoforms showed both modifications enhance receptor internalization and Gαi signaling without biasing toward β-arrestin, refining the PTM tuning model.

    Evidence Chemically synthesized isoforms, neutrophil internalization, BRET β-arrestin, Gαi assays

    PMID:30486423

    Open questions at the time
    • Single-lab study
    • In vivo consequences of these signaling shifts not addressed here
  17. 2020 High

    Defining isoform-selective effects of NH₂-terminal truncation showed length tunes specific activities (actin polymerization, in vivo recruitment) without altering others, demonstrating modular activity control.

    Evidence CXCL8(1-77/6-77/9-77) in neutrophil functional assays and in vivo peritoneal injection

    PMID:32272490

    Open questions at the time
    • Proteases generating CXCL8(9-77) in vivo not identified
    • Receptor-level basis for selective potentiation not resolved
  18. 2021 Medium

    KLF4 was established as a direct negative transcriptional regulator forming a reciprocal feedback loop with CXCL8, co-opted by H. pylori CagA to drive expression.

    Evidence KLF4 siRNA/overexpression, ChIP at CXCL8 promoter, CagA infection model, in vivo tumor growth

    PMID:34038586

    Open questions at the time
    • Single-lab study
    • Mechanism of CXCL8-induced KLF4 downregulation not detailed
  19. 2014 Medium

    Purinergic P2X7/P2Y6 control of CXCL8 secretion revealed tonic and stimulated nucleotide-driven regulation of chemokine output in glioma cells.

    Evidence P2Y6 siRNA, P2X7/P2Y6 antagonists, apyrase, ELISA

    PMID:25445541

    Open questions at the time
    • Single-lab study
    • Downstream transcriptional link to purinergic input not mapped
  20. 2015 Medium

    Showing CXCL8 promotes osteoclastogenesis indirectly via osteoblast IL-6 clarified that its bone effects are paracrine rather than direct on osteoclast precursors.

    Evidence Osteoblast culture with CXCL8, conditioned-medium transfer, IL-6 inhibition, osteoclast assays

    PMID:26103626

    Open questions at the time
    • Single-lab study
    • Receptor mediating osteoblast response not defined
  21. 2019 High

    Solving the CXCL8–Evasin-3 complex defined GAG-site blockade as a structural strategy to disrupt CXCR2 engagement and neutrophil chemotaxis.

    Evidence Solution NMR structure, SPR binding (Kd 13-27 nM), PMN migration inhibition

    PMID:31235521

    Open questions at the time
    • In vivo efficacy of synthetic Evasin variants not established here
    • Selectivity over other chemokines not fully characterized
  22. 2019 Medium

    Autocrine CXCL8/CXCR1-2 signaling in glioblastoma was shown to activate PI3K/Akt/FAK, RhoA/Cdc42, and MMP2 to drive invasion, extending the chemotactic machinery to tumor cell motility.

    Evidence Dual allosteric CXCR1/2 antagonist, Western blot of downstream effectors, migration/invasion assays in GBM cells

    PMID:31986121

    Open questions at the time
    • Single-lab study
    • In vivo invasion not directly tested
  23. 2022 Medium

    Defining the thrombin–ERK–DCLK1–RhoA–YAP/p65 axis added a Hippo-pathway-linked route by which YAP cooperates with p65 at the CXCL8 promoter.

    Evidence DCLK1 siRNA/inhibitor, RhoA assay, YAP fractionation, NF-κB luciferase, ChIP of YAP/p65, asthma tissue and OVA model

    PMID:36369000

    Open questions at the time
    • Single-lab study
    • Integration with the earlier PKCα–c-Src–IKK thrombin route unresolved
  24. 2022 Medium

    Linking EBV/RPMS1–NF-κB–CXCL8 to vasculogenic mimicry in gastric carcinoma showed viral oncogenes drive CXCL8-dependent tumor vascular phenotypes.

    Evidence EBV-infected AGS cells, CXCL8 siRNA, NF-κB inhibitors, RPMS1 overexpression, VM and xenograft assays

    PMID:35321317

    Open questions at the time
    • Single-lab study
    • Receptor(s) and signaling for VM not dissected
  25. 2023 High

    Genetic and pharmacological targeting established CXCL8/CXCR2 as a driver of bone marrow fibrosis in myelofibrosis, providing a therapeutic axis synergizing with JAK inhibition.

    Evidence Single-cell transcriptomics, primary MF cells, Cxcr2 deletion in hMPLW515L model with survival, CXCR1/2 inhibition, JAKi combination

    PMID:36800567

    Open questions at the time
    • Cellular source of CXCL8 in the niche not fully resolved
    • Direct vs indirect fibrotic mechanism not separated
  26. 2023 Medium

    Dissecting cell-intrinsic (PI3K/AKT/NF-κB in GSCs) and cell-extrinsic (CXCR2-JAK2/STAT3 in macrophages) CXCL8 signaling explained its dual role in glioblastoma growth and immune polarization.

    Evidence Patient-derived GSCs, RNA-seq, xenografts, genetic CXCL8/CXCR2 inhibition, pathway inhibitors, macrophage polarization assays

    PMID:37439870

    Open questions at the time
    • Single-lab study
    • Relative contribution of each arm to in vivo growth not quantified
  27. 2024 Medium

    Identifying the DAB2–CXCL8–PI3K/AKT axis in spiral artery remodeling revealed a developmental role driving decidual vascular smooth muscle dedifferentiation.

    Evidence scRNA-seq, DAB2 shRNA, conditioned-medium transfer, PI3K/AKT inhibition, placenta-decidua co-culture

    PMID:38613672

    Open questions at the time
    • Single-lab study
    • Receptor on dVSMCs not specified
  28. 2025 Medium

    Showing CXCL8/CXCR1-2–MAPK signaling drives hnRNP-K cytoplasmic relocalization to promote viral 5'UTR activity revealed a chemokine-co-opting mechanism shared across enterovirus, influenza, and rhinovirus.

    Evidence CXCL8/CXCR1-2 siRNA, MAPK inhibition, hnRNP-K fractionation, viral RNA binding and 5'UTR reporter assays

    PMID:39962077

    Open questions at the time
    • Single-lab study
    • Whether secreted CXCL8 or intracellular signaling predominates in vivo unresolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the multiple transcriptional inputs (NF-κB via distinct cascades, NFAT, ZO-1, YAP, KLF4) and post-translational modifications are integrated to set CXCL8 output and receptor bias in a given physiological or disease context remains unresolved.
  • No unified model reconciling parallel promoter regulators
  • Endogenous proteases/PAD enzymes generating natural isoforms in vivo unidentified
  • Quantitative rules linking oligomeric state and PTMs to CXCR1 vs CXCR2 outcomes lacking

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0048018 receptor ligand activity 3 GO:0060089 molecular transducer activity 3 GO:0008289 lipid binding 2
Localization
GO:0005576 extracellular region 2
Pathway
R-HSA-162582 Signal Transduction 4 R-HSA-168256 Immune System 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-1643685 Disease 3
Partners
CXCR1CXCR2

Evidence

Reading pass · 28 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1988 CXCL8/MDNCF cDNA was cloned from LPS-stimulated human monocyte mRNA, revealing a 99-amino acid precursor with a signal peptide; the mature functional protein comprises 72 amino acids starting at residue 28 (serine). IL-1 and TNF increase MDNCF mRNA >10-fold within 1 hour, and stimulate production of biologically active MDNCF. cDNA cloning, N-terminal amino acid sequencing, mRNA induction assays with IL-1/TNF/LPS The Journal of experimental medicine High 3260265
1989 CXCL8/MDNCF binds specific receptors on human neutrophils: ~20,000 high-affinity binding sites per cell (Kd ~8×10⁻¹⁰ M). Cross-linking identified two receptor polypeptides of ~67 kDa and ~59 kDa. These receptors are distinct from IL-1α, TNF-α, FMLP, C5a, LTB4, and PAF receptors. ¹²⁵I-labeled MDNCF competitive binding, Scatchard analysis, SDS-PAGE of chemically cross-linked receptor–ligand complex The Journal of experimental medicine High 2647892
1989 The N-terminal 10-amino-acid sequence of CXCL8 (AVLPRSAKEL) is sufficient for chemotactic activity toward PMNs (ED50 ~5 nM) and for inducing phosphorylation of a 64-kDa serine-phosphorylated protein in PMNs. The N-terminal peptide alone did not trigger myeloperoxidase or β-glucuronidase release, indicating that granule exocytosis requires additional regions of the full protein. Synthetic peptide chemotaxis assay, ³²P phosphorylation assay, enzyme release assay Biochemical and biophysical research communications Medium 2675839
1990 The IL-8/CXCL8 gene is located on human chromosome 4q12-q21 in a gene cluster with other platelet factor 4 superfamily members (PF4, MGSA/GRO, IP-10). The gene coding region consists of 4 exons and 3 introns. Human cells first produce a mature protein with N-terminal AVLPR (LUCT form), which is then truncated to generate the form lacking this sequence. Human-rodent somatic cell hybrid panel, in situ hybridization, PCR of genomic DNA, restriction fragment length polymorphism analysis Human genetics / Immunology letters High 1967588 2200751
2006 Thrombin induces IL-8/CXCL8 expression in human lung epithelial cells via PAR1 and PAR4 (not PAR3), activating a PKCα → c-Src → IKKαβ → NF-κB signaling cascade. Thrombin promotes complex formation among PKCα, c-Src, and IKKαβ, leading to IκBα phosphorylation/degradation and p65/p50 nuclear translocation, which drives CXCL8 transcription through the κB site in its promoter. Dominant-negative c-Src transfection, PAR agonist peptides, luciferase reporter with κB-site mutation, co-immunoprecipitation of PKCα/c-Src/IKKαβ complex, kinase activity assays Journal of immunology High 16920985
2008 Peptidylarginine deiminase (PAD) citrullinates CXCL8 at arginine-5, generating CXCL8(1-77)Cit5, found naturally on ~14% of leukocyte-derived CXCL8. Citrullination reduces CXCL8 affinity for glycosaminoglycans, decreases CXCR2-dependent calcium signaling and ERK1/2 phosphorylation, confers resistance to thrombin/plasmin-mediated potentiation into CXCL8(6-77), and abolishes neutrophil extravasation in vivo despite retained in vitro chemotactic activity. Natural CXCL8 isolation and characterization, PAD enzymatic citrullination, calcium flux assays, ERK1/2 phosphorylation assays, in vivo peritoneal neutrophil recruitment, rabbit cornea angiogenesis assay The Journal of experimental medicine High 18710930
2009 CXCL8 monomer is more potent than the dimer for intracellular Ca²⁺ mobilization, phosphoinositide hydrolysis, chemotaxis, and exocytosis. Receptor regulation is receptor-specific: monomer preferentially drives CXCR1 phosphorylation, desensitization, β-arrestin translocation, and internalization, whereas both forms regulate CXCR2 equivalently. ERK phosphorylation is more sustained via CXCR2 than CXCR1 for all CXCL8 variants. Trapped nonassociating monomer (L25NMe) and nondissociating dimer (R26C) variants; Ca²⁺ mobilization, PI hydrolysis, chemotaxis, exocytosis, receptor phosphorylation, β-arrestin translocation, and internalization assays in human neutrophils and RBL cells stably expressing CXCR1 or CXCR2 Journal of immunology High 19667085
2005 The CXCR1 inhibitor (R)-ketoprofen/repertaxin binds a site in the transmembrane (TM) region of CXCR1, acting as a noncompetitive allosteric inhibitor of CXCL8-induced PMN chemotaxis. Binding model was confirmed by alanine scanning mutagenesis and photoaffinity labeling, identifying the TM region interaction site. Molecular modeling, alanine scanning mutagenesis, photoaffinity labeling of CXCR1 Journal of medicinal chemistry Medium 15974585
2003 CXCL8 and GROα/CXCL1 induce articular chondrocyte hypertrophy and calcification via CXCR1/CXCR2 signaling through p38 MAPK, resulting in expression of type X collagen, MMP-13, alkaline phosphatase, and TIMP-3. Transglutaminase 2 (TG2) is an essential mediator downstream of p38 for the induction of hypertrophic markers and matrix calcification, as shown using TG2-null mouse chondrocytes. Primary human and bovine chondrocytes, CXCR1/2 ligand specificity experiments, p38 inhibitor studies, TG2-knockout mouse chondrocytes, alkaline phosphatase activity assay, matrix calcification assay Journal of immunology High 14530367
2006 CXCL8-induced chemotaxis via CXCR1 and CXCR2 requires PI3K/Akt and Cbl signaling. CXCL8 stimulation promotes association of the PI3K p85 subunit with Cbl. Overexpression of wild-type Cbl or a TK-binding-domain mutant (G306E) inhibits chemotaxis ~50%, while the RING-finger-deleted mutant (70Z) does not. Kinase-dead Akt reduces chemotaxis by ~60% and diminishes Cbl phosphorylation. Proteasome inhibitors block CXCL8-induced CXCR1/CXCR2 internalization. Dominant-negative and mutant Cbl/Akt overexpression in CXCR1/CXCR2-L1.2 cells, PI3K inhibitor (LY294002), co-immunoprecipitation of p85-Cbl, proteasome inhibitor-mediated receptor internalization assays International immunology Medium 16798838
2019 Evasin-3, a tick salivary protein, directly binds CXCL8 and disrupts its glycosaminoglycan-binding site, preventing CXCL8 interaction with CXCR2 and inhibiting PMN chemotaxis. Solution NMR determined the structure of the CXCL8–Evasin-3 complex. Synthetic Evasin-3 variants (tEv3 17-56, tcEv3 16-56) bind CXCL8 with Kd values of 27 nM and 13 nM (SPR) and inhibit CXCL8-induced neutrophil migration. Solution NMR structure determination, surface plasmon resonance, PMN migration inhibition assay The Journal of biological chemistry High 31235521
2020 NH₂-terminal truncation of CXCL8 strongly potentiates actin polymerization in human neutrophils and enhances in vivo peritoneal neutrophil recruitment (CXCL8(9-77) > CXCL8(6-77)), while not affecting CD62L shedding, adhesion molecule up-regulation, degranulation, phagocytosis, Ca²⁺ signaling, or in vitro directional migration—demonstrating that specific biological activities of CXCL8 are selectively fine-tuned by NH₂-terminal length. Comparison of CXCL8(1-77), CXCL8(6-77), CXCL8(9-77) in human neutrophil functional assays; in vivo peritoneal injection in mice; flow cytometry, actin polymerization assay Journal of leukocyte biology High 32272490
2018 Site-specific citrullination at Arg5 and NH₂-terminal truncation to CXCL8(6-77) both moderately enhance CXCR1 and CXCR2 internalization and increase Gαi-dependent signaling through both receptors. CXCL8(6-77) shows enhanced β-arrestin 2 recruitment to both receptors; [Cit5]CXCL8(1-77) shows enhanced β-arrestin 2 recruitment only to CXCR2. Neither modification biases signaling preference between Gαi and β-arrestin pathways. Chemically synthesized CXCL8 isoforms, human neutrophil internalization assays, BRET-based β-arrestin recruitment assays, Gαi signaling assays International journal of molecular sciences Medium 30486423
2009 PGF₂α–FP receptor signaling induces CXCL8 expression in endometrial adenocarcinoma cells via a PKC-calcium-calcineurin-NFAT pathway. Promoter analysis identified cooperative AP1 and NFAT binding sites as required for transcriptional activation of CXCL8. RCAN1-4 (regulator of calcineurin) is induced reciprocally via the calcineurin/NFAT pathway and acts as a negative regulator of CXCL8 expression, demonstrated by adenoviral RCAN1-4 overexpression. Luciferase reporter assays with CXCL8 promoter mutants, PKC inhibitors, calcium chelation, adenoviral RCAN1-4 overexpression, in vivo nude mouse xenograft Biochimica et biophysica acta Medium 19819266
2017 ZO-1 (zonula occludens-1) regulates CXCL8 transcription via a cytonuclear pool that activates a 173-bp region of the CXCL8 promoter through an NF-κB site. Both IκBα and p65 are phosphorylated in ZO-1-overexpressing cells; p65 siRNA silencing abolishes ZO-1-driven CXCL8 induction. This ZO-1/NF-κB/CXCL8 axis promotes angiogenesis in ex vivo and in vivo assays. ZO-1 siRNA/cDNA transfection, CXCL8 luciferase reporter with NF-κB site mutation, p65 siRNA, ex vivo and in vivo angiogenesis assays FASEB journal Medium 28057697
2011 ZO-1 positively regulates CXCL8/IL-8 expression in breast cancer cells independently of the β-catenin pathway. ZO-1 siRNA (three distinct siRNAs) consistently reduces CXCL8 in invasive BT549 cells; ZO-1 overexpression in non-invasive BT20/SKBR3 cells induces CXCL8. ZO-1 activates the CXCL8 promoter as shown by luciferase reporter assays. GeneArray chemokine profiling, three independent ZO-1 siRNAs, ZO-1 cDNA overexpression, CXCL8 luciferase promoter assay Molecular cancer research Medium 22064657
2022 Thrombin induces IL-8/CXCL8 expression via a DCLK1 → RhoA → YAP signaling axis in human lung epithelial cells. ERK activates DCLK1, which in turn activates RhoA and dephosphorylates YAP at Ser127, allowing YAP nuclear translocation and formation of a YAP/p65 complex that binds the NF-κB site of the CXCL8 promoter to drive transcription. DCLK1 siRNA and pharmacological inhibitor, RhoA activity assay, YAP phosphorylation and nuclear translocation (Western blot, fractionation), NF-κB luciferase reporter, ChIP assay for YAP and p65 at CXCL8 promoter, asthma patient tissue and OVA mouse model Journal of biomedical science Medium 36369000
2011 CXCR1 and CXCR2 are functionally required for CXCL8-dependent endothelial cell proliferation, survival, migration, invasion, and capillary-like structure formation. shRNA knockdown of CXCR1 and/or CXCR2 in HMEC-1 cells inhibits these processes and abolishes CXCL8-induced ERK phosphorylation and cytoskeletal rearrangement. shRNA knockdown of CXCR1/CXCR2 in human microvascular endothelial cells, ERK phosphorylation assay, cytoskeletal analysis, proliferation/migration/invasion/tube-formation assays Microvascular research Medium 21749879
2023 CXCL8/CXCR2 signaling drives bone marrow fibrosis in myelofibrosis. Hematopoietic stem/progenitor cells from MF patients display enriched CXCL8/CXCR2 gene signatures and enhanced proliferation in response to exogenous CXCL8 in vitro. Genetic deletion of Cxcr2 in the hMPLW515L murine adoptive transfer model abrogates fibrosis and extends survival. Pharmacologic CXCR1/2 inhibition improves hematologic parameters, attenuates fibrosis, and synergizes with JAK inhibitor therapy. Single-cell transcriptomics, cytokine secretion studies of primary MF patient cells, Cxcr2 genetic deletion in murine adoptive transfer model, pharmacological CXCR1/2 inhibition, JAK inhibitor combination studies Blood High 36800567
2019 Autocrine CXCL8 signaling through CXCR1/CXCR2 in glioblastoma cells activates PI3K/p-Akt/p-FAK, p-cortactin, RhoA, Cdc42, acetylated α-tubulin, and MMP2 pathways to drive invasiveness and cytoskeletal dynamics. CXCR1/CXCR2 dual allosteric antagonist blockade reduces these signaling events and suppresses migration/invasion. CXCR1/CXCR2 dual allosteric antagonist treatment of primary GBM cells and U-87MG, Western blot for PI3K/Akt/FAK/cortactin/RhoA/Cdc42/α-tubulin/MMP2, migration and invasion assays Aging Medium 31986121
2023 CXCL8 activates PI3K/AKT and NF-κB signaling in glioblastoma stem cells (GSCs) to maintain self-renewal and survival (cell-intrinsic), and activates CXCR2-JAK2/STAT3 signaling in tumor-associated macrophages to drive M2-like polarization (cell-extrinsic). Combined genetic and pharmacological inhibition of these dual signaling cascades suppresses tumor growth and prolongs survival in orthotopic xenograft mice. Patient-derived GSCs, RNA sequencing, xenograft murine model, genetic CXCL8/CXCR2 inhibition, pharmacological PI3K/AKT/NF-κB/JAK2/STAT3 inhibitors, macrophage polarization assays Clinical cancer research Medium 37439870
2025 CXCL8 is an early response gene to EV-D68 infection. CXCL8 binding to CXCR1/2 activates the MAPK pathway, which facilitates translocation of nuclear hnRNP-K to the cytoplasm, where it binds viral RNA and promotes activity of the viral 5' UTR to enhance replication. Silencing CXCL8 or CXCR1/2 impedes EV-D68 replication in vitro; this pathway also supports influenza virus and rhinovirus replication. CXCL8 and CXCR1/2 siRNA knockdown, MAPK pathway inhibition, hnRNP-K nuclear/cytoplasmic fractionation, viral RNA binding assay, 5' UTR reporter assay Nature communications Medium 39962077
2022 NF-κB signaling mediates EBV-induced CXCL8 upregulation in gastric carcinoma cells; CXCL8 promotes vasculogenic mimicry (VM) formation via NF-κB. EBV-encoded lncRNA RPMS1 activates NF-κB, which is required for EBV-induced VM. NF-κB inhibitors BAY 11-7082 and BMS345541 block CXCL8-induced VM. EBV-infected AGS cell model, CXCL8 siRNA knockdown, NF-κB inhibitors, RPMS1 lncRNA overexpression, tube formation/VM assay, xenograft model Frontiers in cellular and infection microbiology Medium 35321317
2021 KLF4 binds the CXCL8 promoter and suppresses CXCL8 transcription, acting as a negative transcriptional regulator. KLF4 knockdown increases CXCL8 expression, while overexpression reduces it. Reciprocally, CXCL8 stimulation reduces KLF4 protein expression, forming a negative feedback loop. H. pylori CagA protein upregulates CXCL8 and inhibits KLF4. KLF4 siRNA and overexpression, ChIP assay demonstrating KLF4 binding to CXCL8 promoter, H. pylori/CagA infection model, migration and proliferation assays, in vivo tumor growth Molecular carcinogenesis Medium 34038586
2014 CXCL8 secretion from glioma cells is controlled by purinergic receptor activation: P2X7 and P2Y6 receptors modulate LPS-induced CXCL8 release. P2Y6 knockdown reduces both LPS-induced and basal CXCL8 release, indicating tonic purinergic regulation of CXCL8 production. P2Y6 siRNA knockdown, P2X7/P2Y6 pharmacological antagonists (suramin, MRS2578), apyrase nucleotide scavenging, ELISA Biochimica et biophysica acta Medium 25445541
2008 Human Thy-1 interaction with neutrophil integrin Mac-1 (CD18) stimulates secretion of both CXCL8 and MMP-9 from neutrophils, enhancing their migration through collagen-IV and matrigel. Blocking Thy-1 or CD18 abolishes these responses. Neutrophil adhesion to recombinant Thy-1, blocking antibodies against Thy-1 and CD18, MMP-9 secretion assay, CXCL8 ELISA, collagen-IV and matrigel migration assay European journal of immunology Medium 18389476
2015 CXCL8 and CCL20 enhance osteoblast-mediated osteoclastogenesis through increased osteoblast IL-6 production; IL-6 inhibition reduces the stimulatory effect of CXCL8-conditioned medium on osteoclast formation. CXCL8 does not directly stimulate osteoclast precursors, indicating its pro-osteoclastogenic effect is indirect, mediated via osteoblast IL-6. Human primary osteoblast culture with CXCL8/CCL20, conditioned medium transfer to osteoclast precursors, IL-6 inhibitor treatment, osteoclast formation and resorption assay PloS one Medium 26103626
2024 CXCL8 is a pivotal regulator of decidual vascular smooth muscle cell (dVSMC) dedifferentiation in uterine spiral artery remodeling. DAB2 expression in extravillous trophoblasts (EVTs) controls CXCL8 secretion, and CXCL8 drives dVSMC phenotypic transition through the CXCL8/PI3K/AKT pathway, as demonstrated in cell models and a placenta-decidua co-culture model. Single-cell RNA sequencing, DAB2 shRNA knockdown, conditioned medium transfer from HTR-8/SVneo cells to hVSMCs, PI3K/AKT inhibition, placenta-decidua co-culture model Cellular and molecular life sciences Medium 38613672

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1988 Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. The Journal of experimental medicine 1053 3260265
2017 Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases. Theranostics 620 28529637
2016 The CXCL8-CXCR1/2 pathways in cancer. Cytokine & growth factor reviews 523 27578214
2014 The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases. Expert review of clinical immunology 517 24678812
2023 The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention. Cellular & molecular immunology 434 36725964
2009 Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 372 19904283
2003 Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. American journal of physiology. Lung cellular and molecular physiology 355 12618418
2019 Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer. Gut 314 30661053
2009 CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer. International journal of cancer 246 19035451
2009 Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer. Journal of immunology (Baltimore, Md. : 1950) 159 19667085
1989 Identification and characterization of specific receptors for monocyte-derived neutrophil chemotactic factor (MDNCF) on human neutrophils. The Journal of experimental medicine 159 2647892
2003 IL-8/CXCL8 and growth-related oncogene alpha/CXCL1 induce chondrocyte hypertrophic differentiation. Journal of immunology (Baltimore, Md. : 1950) 155 14530367
2008 Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. The Journal of experimental medicine 147 18710930
2022 Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8. Science advances 127 35319989
2009 Expression of zebrafish cxcl8 (interleukin-8) and its receptors during development and in response to immune stimulation. Developmental and comparative immunology 119 19941893
1990 Monocyte-derived neutrophil chemotactic factor (MDNCF/IL-8) resides in a gene cluster along with several other members of the platelet factor 4 gene superfamily. Human genetics 117 1967588
2004 Increased CXCL8 (IL-8) expression in Multiple Sclerosis. Journal of neuroimmunology 110 15342208
2021 Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy. Molecules (Basel, Switzerland) 101 35011369
2022 CXCL8 in Tumor Biology and Its Implications for Clinical Translation. Frontiers in molecular biosciences 97 35372515
2016 MicroRNA-146a in Human and Experimental Ischemic AKI: CXCL8-Dependent Mechanism of Action. Journal of the American Society of Nephrology : JASN 85 27444565
2005 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. Journal of medicinal chemistry 85 15974585
2021 CXCL8 chemokine in ulcerative colitis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 80 33706134
2013 The Chemokine CXCL8 in Carcinogenesis and Drug Response. ISRN oncology 80 24224100
2018 IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis. JCI insight 71 30135299
2011 CXCR1 and CXCR2 silencing modulates CXCL8-dependent endothelial cell proliferation, migration and capillary-like structure formation. Microvascular research 69 21749879
2016 Tumor-associated macrophage-derived CXCL8 could induce ERα suppression via HOXB13 in endometrial cancer. Cancer letters 66 27018308
2019 Autophagy enhances mesenchymal stem cell-mediated CD4+ T cell migration and differentiation through CXCL8 and TGF-β1. Stem cell research & therapy 60 31443687
2019 The Crucial Role of CXCL8 and Its Receptors in Colorectal Liver Metastasis. Disease markers 59 31827643
2014 Nucleotide receptors control IL-8/CXCL8 and MCP-1/CCL2 secretions as well as proliferation in human glioma cells. Biochimica et biophysica acta 57 25445541
2019 Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer. Frontiers in immunology 56 31105691
2021 CXCL8 Associated Dendritic Cell Activation Marker Expression and Recruitment as Indicators of Favorable Outcomes in Colorectal Cancer. Frontiers in immunology 51 34025668
2008 Expression of CXCL8, CXCR1, and CXCR2 in neurons and glial cells of the human and rabbit retina. Investigative ophthalmology & visual science 51 18552386
2023 CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis. Blood 50 36800567
2011 CXCL8 of Scophthalmus maximus: expression, biological activity and immunoregulatory effect. Developmental and comparative immunology 49 21530579
2023 Spatially resolved transcriptomics reveals pro-inflammatory fibroblast involved in lymphocyte recruitment through CXCL8 and CXCL10. eLife 48 36648332
2009 Prostaglandin F(2alpha)-F-prostanoid receptor regulates CXCL8 expression in endometrial adenocarcinoma cells via the calcium-calcineurin-NFAT pathway. Biochimica et biophysica acta 48 19819266
2006 c-Src mediates thrombin-induced NF-kappaB activation and IL-8/CXCL8 expression in lung epithelial cells. Journal of immunology (Baltimore, Md. : 1950) 46 16920985
2021 An updated review on the role of the CXCL8-CXCR1/2 axis in the progression and metastasis of breast cancer. Molecular biology reports 44 34426905
2008 Roles of CXCL8 in squamous cell carcinoma proliferation and migration. Oral oncology 44 18282785
2023 Dual Role of CXCL8 in Maintaining the Mesenchymal State of Glioblastoma Stem Cells and M2-Like Tumor-Associated Macrophages. Clinical cancer research : an official journal of the American Association for Cancer Research 41 37439870
2019 PTPRD-inactivation-induced CXCL8 promotes angiogenesis and metastasis in gastric cancer and is inhibited by metformin. Journal of experimental & clinical cancer research : CR 41 31805999
2015 CXCL8 and CCL20 Enhance Osteoclastogenesis via Modulation of Cytokine Production by Human Primary Osteoblasts. PloS one 40 26103626
2018 Molecular characterization and functional activity of CXCL8_L3 in large yellow croaker Larimichthys crocea. Fish & shellfish immunology 37 29367006
2011 Visfatin enhances CXCL8, CXCL10, and CCL20 production in human keratinocytes. Endocrinology 36 21673103
2023 CXCL8 induces M2 macrophage polarization and inhibits CD8+ T cell infiltration to generate an immunosuppressive microenvironment in colorectal cancer. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 35 37665572
2018 ShRNA-mediated knock-down of CXCL8 inhibits tumor growth in colorectal liver metastasis. Biochemical and biophysical research communications 34 29679563
2014 Cxcl8-l1 and Cxcl8-l2 are required in the zebrafish defense against Salmonella Typhimurium. Developmental and comparative immunology 32 25445910
2019 Human Brain Endothelial CXCR2 is Inflammation-Inducible and Mediates CXCL5- and CXCL8-Triggered Paraendothelial Barrier Breakdown. International journal of molecular sciences 30 30704100
2020 Truncation of CXCL8 to CXCL8(9-77) enhances actin polymerization and in vivo migration of neutrophils. Journal of leukocyte biology 28 32272490
2017 Zonula occludens-1/NF-κB/CXCL8: a new regulatory axis for tumor angiogenesis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 28 28057697
2015 99mTc-CXCL8 SPECT to Monitor Disease Activity in Inflammatory Bowel Disease. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 28 26609182
2006 Cbl and Akt regulate CXCL8-induced and CXCR1- and CXCR2-mediated chemotaxis. International immunology 28 16798838
2005 Endothelin-1 induces CXCL1 and CXCL8 secretion in human melanoma cells. The Journal of investigative dermatology 27 16098041
2017 Adiponectin promotes human jaw bone marrow mesenchymal stem cell chemotaxis via CXCL1 and CXCL8. Journal of cellular and molecular medicine 26 28176455
2022 CXCL8, CXCL9, CXCL10, and CXCL11 as biomarkers of liver injury caused by chronic hepatitis B. Frontiers in microbiology 25 36504808
2021 H. pylori infection induces CXCL8 expression and promotes gastric cancer progress through downregulating KLF4. Molecular carcinogenesis 25 34038586
2013 MMP-9 and CXCL8/IL-8 are potential therapeutic targets in epidermolysis bullosa simplex. PloS one 25 23894602
2013 T lymphocyte-dependent and -independent regulation of Cxcl8 expression in zebrafish intestines. Journal of immunology (Baltimore, Md. : 1950) 25 24277695
2011 Regulation of CXCL8/IL-8 expression by zonula occludens-1 in human breast cancer cells. Molecular cancer research : MCR 25 22064657
2021 The Role of Chemokines in Cardiovascular Diseases and the Therapeutic Effect of Curcumin on CXCL8 and CCL2 as Pathological Chemokines in Atherosclerosis. Advances in experimental medicine and biology 24 34981477
2020 CXCL5, CXCL8, and CXCL10 regulation by bacteria and mechanical forces in periodontium. Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft 24 33221386
2019 Tick saliva protein Evasin-3 modulates chemotaxis by disrupting CXCL8 interactions with glycosaminoglycans and CXCR2. The Journal of biological chemistry 24 31235521
2015 Gemcitabine-induced CXCL8 expression counteracts its actions by inducing tumor neovascularization. Biochemical and biophysical research communications 24 25646691
2022 CXCL8, MMP12, and MMP13 are common biomarkers of periodontitis and oral squamous cell carcinoma. Oral diseases 23 36321868
1989 Localization of chemotactic activity and 64 kD protein phosphorylation for human polymorphonuclear leukocytes in N-terminus of the chemotactic protein LUCT/IL-8. Biochemical and biophysical research communications 23 2675839
2019 Consensus-Expressed CXCL8 and MMP9 Identified by Meta-Analyzed Perineural Invasion Gene Signature in Gastric Cancer Microarray Data. Frontiers in genetics 21 31681401
2016 CXCL8 as a Potential Therapeutic Target for HIV-Associated Neurocognitive Disorders. Current drug targets 21 26112047
2014 Regulatory mechanisms of betacellulin in CXCL8 production from lung cancer cells. Journal of translational medicine 20 24629040
2014 [CXCL8 (interleukin 8)--the key inflammatory mediator in chronic obstructive pulmonary disease?]. Postepy higieny i medycyny doswiadczalnej (Online) 20 24988605
2021 CXCL8 Facilitates the Survival and Paclitaxel-Resistance of Triple-Negative Breast Cancers. Clinical breast cancer 19 34284965
2018 Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. Journal of immunology (Baltimore, Md. : 1950) 19 29802127
2024 IL-8 (CXCL8) Correlations with Psychoneuroimmunological Processes and Neuropsychiatric Conditions. Journal of personalized medicine 18 38793070
2021 Serum CXCL8 and Its Specific Receptor (CXCR2) in Gastric Cancer. Cancers 18 34680333
2020 The role of PKC in CXCL8 and CXCL10 directed prostate, breast and leukemic cancer cell migration. European journal of pharmacology 18 32777211
2018 Differential Effects of Posttranslational Modifications of CXCL8/Interleukin-8 on CXCR1 and CXCR2 Internalization and Signaling Properties. International journal of molecular sciences 18 30486423
2022 Thrombin induces IL-8/CXCL8 expression by DCLK1-dependent RhoA and YAP activation in human lung epithelial cells. Journal of biomedical science 17 36369000
2018 CXCL8 hyper-signaling in the aortic abdominal aneurysm. Cytokine 17 29587155
1990 Coding region structure of interleukin-8 gene of human lung giant cell carcinoma LU65C cells that produce LUCT/interleukin-8: homogeneity in interleukin-8 genes. Immunology letters 17 2200751
2022 EBV-Induced CXCL8 Upregulation Promotes Vasculogenic Mimicry in Gastric Carcinoma via NF-κB Signaling. Frontiers in cellular and infection microbiology 16 35321317
2022 The CDK1-Related lncRNA and CXCL8 Mediated Immune Resistance in Lung Adenocarcinoma. Cells 16 36078096
2012 Combined effects of CXCL8 and CXCR2 gene polymorphisms on susceptibility to systemic sclerosis. Cytokine 16 22763041
2025 CXCL8 modulates M0 macrophage proliferation and polarization to influence tumor progression in cervical cancer. Scientific reports 15 39755693
2011 Targeting of a common receptor shared by CXCL8 and N-Ac-PGP as a therapeutic strategy to alleviate chronic neutrophilic lung diseases. European journal of pharmacology 15 21669195
2008 Human Thy-1 induces secretion of matrix metalloproteinase-9 and CXCL8 from human neutrophils. European journal of immunology 15 18389476
2023 PFOA, PFHxA and C6O4 differently modulate the expression of CXCL8 in normal thyroid cells and in thyroid cancer cell lines. Environmental science and pollution research international 14 37052835
2020 Autocrine CXCL8-dependent invasiveness triggers modulation of actin cytoskeletal network and cell dynamics. Aging 14 31986121
2017 Metformin Suppressed CXCL8 Expression and Cell Migration in HEK293/TLR4 Cell Line. Mediators of inflammation 14 29147073
2010 CXCL8 attenuates chemoattractant-induced equine neutrophil migration. Veterinary immunology and immunopathology 14 21040981
2024 Identification of the role of DAB2 and CXCL8 in uterine spiral artery remodeling in early-onset preeclampsia. Cellular and molecular life sciences : CMLS 13 38613672
2023 Guanylate binding protein 5 accelerates gastric cancer progression via the JAK1-STAT1/GBP5/CXCL8 positive feedback loop. American journal of cancer research 13 37168340
2022 FOXS1 Promotes Tumor Progression by Upregulating CXCL8 in Colorectal Cancer. Frontiers in oncology 13 35898871
2025 The CXCL8/MAPK/hnRNP-K axis enables susceptibility to infection by EV-D68, rhinovirus, and influenza virus in vitro. Nature communications 12 39962077
2024 NUCB2 inhibition antagonizes osteosarcoma progression and promotes anti-tumor immunity through inactivating NUCKS1/CXCL8 axis. Cancer letters 12 38636892
2024 CXCL5/CXCL8 induces neutrophilic inflammation in peri-implantitis. Journal of periodontal research 12 38699841
2022 CXCL8 expression is associated with advanced stage, right sidedness, and distinct histological features of colorectal cancer. The journal of pathology. Clinical research 12 35879507
2021 The Cellular and Chemical Biology of Endocytic Trafficking and Intracellular Delivery-The GL-Lect Hypothesis. Molecules (Basel, Switzerland) 12 34072622
2021 Overexpression of CXCL8 gene in Saudi colon cancer patients. Saudi journal of biological sciences 12 34764737
2021 LECT-2 amyloidosis: what do we know? Journal of investigative medicine : the official publication of the American Federation for Clinical Research 12 34848562
2016 New Markers in Atherosclerosis: Thrombospondin-2 (THBS-2) and Leukocyte Cell-Derived Chemotaxin-2 (LECT-2); An Immunohistochemical Study. Medical science monitor : international medical journal of experimental and clinical research 12 28039493
2021 Salivary and gingival CXCL8 correlation with periodontal status, periodontal pathogens, and smoking. Oral diseases 11 34388304

Missed literature

Know a paper Affinage missed for CXCL8? Flag it for the maintainers and the community.

No submissions yet.